EM || News

No ACS approvals for rivaroxaban, Janssen announces

Posted on: 14/02/2014 - 18:10

As expected, the Food and Drug Administration has declined to approve the oral anticoagulant rivaroxaban for treating acute coronary syndromes. The manufacturer of the factor Xa inhibitor, Janssen...

Field of Interest: Cardiology

Type: News Item

Pancytopenia warning added to label of hepatitis C drug boceprevir

Posted on: 13/02/2014 - 21:55

A warning about cases of pancytopenia linked to the use of the oral hepatitis C antiviral drug boceprevir has been added to the drug’s label, the Food and Drug Administration has announced. There...

Field of Interest: Infectious diseases

Type: News Item

Pancytopenia warning added to label of hepatitis C drug boceprevir

Posted on: 13/02/2014 - 21:55

Field of Interest: Oncology

Type: News Item

FDA panel votes against cangrelor approval for PCI, bridge indications

Posted on: 13/02/2014 - 16:25

SILVER SPRING, MD. – A Food and Drug Administration advisory panel, citing numerous problems with cangrelor’s clinical trial program, has recommended against approval of the short-acting intravenous...

Field of Interest: Cardiology

Type: News Item

Exam-room posters cut inappropriate antibiotics prescriptions

Posted on: 27/01/2014 - 21:00

Exam-room posters declaring a clinician’s commitment to make appropriate antibiotics prescriptions may be a simple, low-cost approach to reducing inappropriate use of antibiotics for acute...

Field of Interest: Infectious diseases

Type: News Item

Newsletters

Stay informed on our latest news!

You are here

No ACS approvals for rivaroxaban, Janssen announces

Pancytopenia warning added to label of hepatitis C drug boceprevir

Pancytopenia warning added to label of hepatitis C drug boceprevir

FDA panel votes against cangrelor approval for PCI, bridge indications

Exam-room posters cut inappropriate antibiotics prescriptions

Newsletters

Latest Newsletters